BioPharma Resources

Drug Trial Radar · NCT00069784

The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)

Last checked: Nov 19, 2026Latest source record: Jan 31, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 12,537 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,537

Actual

Start

Aug 2003

Primary completion

Dec 2011

Study completion Dec 2011

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Population Health Research Institute
First posted
Oct 6, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of the ORIGIN study were: * To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or early type 2 diabetes; * To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes. The secondary objectives of the insulin glargine study were to determine if insulin glargine-mediated normoglycemia can reduce: * total mortality (all causes); * the risk of diabetic microvascular outcomes; * the rate of progression of IGT or IFG to type 2 diabetes.

Conditions

  • Diabetes Mellitus, Non-Insulin-Dependent

Interventions

  • insulin glargine (HOE901)Drug

    Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection

  • omega-3 polyunsaturated fatty acids (PUFA)Drug

    Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration

  • placeboDrug

    Matching placebo gelatin capsules (containing olive oil) for oral administration

  • reusable pen device for insulin injectionDevice

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI) or Nonfatal StrokeTime frame: from randomization until study cut-off date (median duration of follow-up: 6.2 years)
  2. Composite of the First Occurrence of Cardiovascular (CV) Death, Nonfatal Myocardial Infarction (MI), Nonfatal Stroke, Revascularization Procedure or Hospitalization for Heart Failure (HF)Time frame: from randomization until study cut-off date (median duration of follow-up: 6.2 years)

Locations

40 sites in 40 countries. Site status is shown where the registry gives one.

  • Sanofi-Aventis Administrative Office

    Bridgewater, New Jersey

  • Sanofi-Aventis Administrative Office

    Buenos Aires, Argentina

  • Sanofi-Aventis Administrative Office

    Cove, New South Wales, Australia

  • Sanofi-Aventis Administrative Office

    Vienna, Austria

  • Sanofi-Aventis Administrative Office

    Minsk, Belarus

  • Sanofi-Aventis Administrative Office

    Hamilton, Bermuda

  • Sanofi-Aventis Administrative Office

    São Paulo, Brazil

  • Sanofi-Aventis Administrative Office

    Laval, Quebec, Canada

  • Sanofi-Aventis Administrative Office

    Santiago, Chile

  • Sanofi-Aventis Administrative Office

    Beijing, China

  • Sanofi-Aventis Administrative Office

    Cali, Colombia

  • Sanofi-Aventis Administrative Office

    Zagreb, Croatia

  • Sanofi-Aventis Administrative Office

    Hørsholm, Denmark

  • Sanofi-Aventis Administrative Office

    Tatari, Estonia

  • Sanofi-Aventis Administrative Office

    Helsinki, Finland

  • Sanofi-Aventis Administrative Office

    Paris, France

  • Sanofi-Aventis Administrative Office

    Berlin, Germany

  • Sanofi-Aventis Administrative Office

    Budapest, Hungary

  • Sanofi-Aventis Administrative Office

    Mumbai, India

  • Makati City

    Dublin, Ireland

  • Sanofi-Aventis Administrative Office

    Netanya, Israel

  • Sanofi-Aventis Administrative Office

    Milan, Italy

  • Sanofi-Aventis Administrative Office

    Riga, Latvia

  • Sanofi-Aventis Administrative Office

    Vilnius, Lithuania

  • Sanofi-Aventis Administrative Office

    México, Mexico

  • Sanofi-Aventis Administrative Office

    Gouda, Netherlands

  • Sanofi-Aventis Administrative Office

    Lysaker, Norway

  • Sanofi-Aventis Administrative Office

    Makati City, Philippines

  • Sanofi-Aventis Administrative Office

    Warsaw, Poland

  • Sanofi-Aventis Administrative Office

    Bucharest, Romania

  • Sanofi-Aventis Aministrative Office

    Moscow, Russia

  • Sanofi-Aventis Administrative Office

    Bratislava, Slovakia

  • Sanofi-Aventis Administrative Office

    Midrand, South Africa

  • Sanofi-Aventis Administrative Office

    Seoul, South Korea

  • Sanofi-Aventis Administrative Office

    Barcelona, Spain

  • Sanofi-Aventis Administrative Office

    Bromma, Sweden

  • Sanofi-Aventis Administrative Office

    Geneva, Switzerland

  • Sanofi-Aventis Administrative Office

    Istanbul, Turkey (Türkiye)

  • Sanofi-Aventis Administrative Office

    Guildford, Surrey, United Kingdom

  • Makati City

    Caracas, Venezuela

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.